AI FOR PHARMA 2026 - AI赋能制药峰会

Meeting Overview

Highlights

•Full-Chain Coverage: Deep Dive into Three Core Areas – Early R&D, Clinical Trials, and Process Development with Smart Manufacturing
•Top-tier lineup: 50+ pharmaceutical executives and C-level leaders from AI service providers
•Real-world case studies: 30 + First public sharing of commercially viable AI implementation practices

AI FOR PHARMA CONFERENCE 2026: Empowering the Future of Pharmaceutical Manufacturing with AI Across the Entire Value Chain, from Early R&D to Process Production. Focused on technology deployment, commercialization, and ecosystem collaboration, this premier industry event connects early drug discovery, clinical research, CMC process development, and smart manufacturing. It brings together pharmaceutical executives, technical leaders, and AI decision-makers to foster cross-industry innovation and accelerate the transition of AI from lab research to scalable industrial applications.

Schedule Framework

View Full Forum Schedule

AI for Pharma 2026 Schedule Framework

8 6 (Day 1)

09:00-11:00 | AI FOR PHARMA 2026 Opening Forum

11:00-12:00 | Lunch Exhibition Tour

12:00-14:00 | AI-Driven Innovation in Drug R&D and Applications

Planning: Tianwu Technology

14:00-15:00 | Tea Break & Exhibition Tour

15:00-18:00 | AI in CMC & Intelligent Manufacturing

8 7 (Day 2)

09:00-11:00 | AI for Science

11:00-12:00 | Lunch Exhibition Tour

12:00-14:00 | AI in Drug Discovery & Early R&D

14:00-16:00 | Brain-Computer Interface

Detailed Schedule

8 6

09:00-11:00 | AI FOR PHARMA 2026 Opening Forum

09:30-09:50 | Report: The Intersection of AI and Life Sciences

Guest: Xu Tian, Chair Professor of Life Sciences, Westlake University

09:50-10:20 | Dialogue: From the Internet to Large Models—An Alternative Approach to AI in Healthcare

10:20-11:00 | Roundtable Discussion: The Real Battlefield of AI in Pharma – How Far Are We from "Using AI" to "Being Transformed by AI"?

Moderator: Luo Fe, Founding Partner of Songhe Capital

Speakers: Shen Yulei, President & CEO of Biotest; Lai Caida, Co-founder & CEO of Jitai Technology; Zhang Yan, Co-founder and Senior Vice President of Magia Technology

12:00-14:00 | AI-Powered Innovation in Drug R&D and Application (Planned by Tianwu Technology)

12:00-12:20 | Report: MatwingsVenus™ Empowering Innovation in Protein R&D

Guest: Li Mingchen, Head of AI Lab at Tianwu Technology

Outline: 1. Technical Breakthroughs in Protein Language Models 2. From Conversational Interaction to Fully Automated Experimental Validation Agents 3. Industrial Implementation of AI-Driven Protein Design in Biomanufacturing

12:20-12:40 | Report: Large Models and Multi-Agent Systems Accelerating Innovative Drug Discovery and Progress

Guest: Li Song, Tianwu Technology, Head of AI-Driven Biopharmaceutical R&D

Outline: 1. Advances in AI Protein Design Methodologies 2. Intelligence and Automation in AI Protein Design 3. Industry Practices and Future Trends in AI-Driven Macromolecule Drug Development

12:40-13:00 | Report: Applications and Future Prospects of AI-Driven Protein Design in Gene Therapy

Guest: Yu Chao Gai, Senior Vice President of R&D, Shengwu Pharmaceutical Technology Co., Ltd.

Outline: 1. How AI-Driven Protein Design Overcomes Key Bottlenecks in Gene Therapy 2. Case Studies in Deployment: a. AI-Designed Gene Editing Tools — Breaking Natural Enzyme Evolution Limits b. AI-Designed Viral Delivery Vectors — Solving Targeting and Scalability Challenges c. AI-Designed Therapeutic Effector Proteins — From "Natural Templates" to "On-Demand Customization" 3. Current Industry Technical Optimization, Pipeline Strategy, and Open Platforms 4. Future Outlook: Anticipated Technical Milestones, Industrialization Trends, and Industry Challenges

13:00-14:00 | Interview: How AI is Reshaping Key Stages and the Future of Innovative Drug R&D

Host: Duan Qing, Shengwu Pharmaceutical, CSO

Speakers: Dai Han, Chief Innovation Officer & Head of Investment & Strategy, Viera Biopharma; Lu Heng, CSO, Akebi Therapeutics; Shi Lei, Senior Vice President, Beiing Bio; Du Zengmin, CMC Vice President, Belief Medicine; Yang Xinyi, Head of AIDD, Henlius.

15:00-18:00 | AI in CMC & Intelligent Manufacturing

15:00-15:40 | Interview: Smart Factory Construction and Digital Prospects

Speakers: Ma Jun, former Deputy General Manager of Junshi Biosciences, Ph.D.; Lin Dongqiang, Professor at the School of Chemical and Biological Engineering, Zhejiang University; Ni Hua, VP at Maiwei Biologics; Jason Li, Senior Vice President of CMC at Tenomone Biopharma; Shen Juping, Senior Vice President at Beihai Kangcheng.

15:40-16:00 | Report: Empowering Future Innovation: Continuous Flow and Automation Driving Customer Value Transformation

Guest: Xu Shuting, Director of Clinical Production Business Unit at WuXi Biologics

16:00-16:20 | Report: Applications of AI in Pharmaceutical Commercialization

Guest: Yu Jin, Head of AI Big Data Analytics, Novartis

Outline: 1. Commercial AI Application Map 2. From Exceptional Execution to Empowering Medicine: How We Are Implementing AI-Driven Innovation 3. Looking Ahead: The Solid Foundation of the AI Blueprint

16:20-16:40 | Report: Fosun Pharma's AI and Digital Intelligence Strategy Deployment and Implementation Progress

Guest: Junyi Ma, Head of AI Strategy & Development and PMO of the AI Innovation Committee at Fosun Pharma

16:40-17:00 | Report: Hybrid AI and Mechanistic Modeling and Applications

Guest: Dongqiang Lin, Professor of Chemical Engineering and Biomedical Engineering, Zhejiang University

Outline: 1. Digitalization and intelligence are key trends in biopharmaceuticals 2. AI-driven mechanistic models enable precise, rapid process modeling 3. Digital twins empower rational design and intelligent manufacturing

17:00-17:20 | Report: Application of AI Platforms in Pharmaceutical Research

Guest: Tang Defang, Deputy General Manager, Chengdu Jingze Biotechnology

Outline: 1. Introduction to AI Agent Features 2. AI Agent Resource Allocation 3. Application of AI Agents in Pharmaceutical Research

17:20-17:40 | Report: Adaptive AI – From Potential to Controlled Use in Biopharma Digital Compliance Architecture for Trustworthy Adaptive AI-Enabled Systems from Process Development to GxP Manufacturing

Speakers: Oliver Herrmann, CEO of Q-FINITY Quality Management; Martin Heitmann, Managing Director of MH Consulting & Advisory

Outline: 1.Introduction: Adaptive AI Meets Regulatory Requirements; 2.Ambition Aligns with Biopharma Reality: A Shift in the Validation Paradigm Is Needed; 3. A Practical Step Forward: Control Architecture for Adaptive GMP Systems with Embedded Data Integrity; 4. Use Case Insights: Lessons from a Real-World Implementation of Adaptive AI in GMP Manufacturing

8 7

09:00-11:00 | AI for Science

09:00-09:20 | Report: The Breakthrough in AI Drug Discovery: From "Efficiency Race" to "Disease Understanding Revolution"

Guest: Zhao Yu, Co-founder of Zheyuan Technology & Deputy Director of the Turing-Darwin Laboratory

Outline: 1. AI's capability to decode complex disease systems through first principles of biological modeling; 2. Showcase of the world's first virtual clinical trial results; 3. Clinical implementation of biological models guided by computational medicine.

09:20-09:40 | Report: Pending

Guest: Liu Xin, Associate Professor at Xi'an Jiaotong-Liverpool University

09:40-10:00 | Report: From Milliseconds to Mechanisms — Behavioromics Engine Powers AI-Driven Precision Neurology, Unlocking the Window for CNS New Drug Development

Guest: Zhou Xianbo, CEO of Asenlai

10:00-10:20 | Report: AI-Driven Organoid-Based Development of Innovative Tumor Targeted Therapies

Guest: Zhang Haisheng, Founder and CEO of Xisigen Biotech

Outline: 1 Leveraging our proprietary "Organoid + AI" platform, we developed SIGX1, the world's first targeted therapy for diffuse gastric cancer to enter clinical trials. 094 2 Utilizing organoids for precise target discovery and efficacy evaluation, combined with AI-driven drug design, we enhance new drug development efficiency and clinical translation success rates.

10:20-10:40 | Report: AI for Science Agents Drive Intelligent Upgrades in Drug Discovery

Guest: Zhang Peng, General Manager of the Biopharmaceutical Business Unit at DeepModeling

10:40-11:00 | Report: Pending

Guest: Jitai Technology

12:00-14:00 | AI in Drug Discovery & Early R&D

12:00-12:20 | Report: Where AI Fits in Early R&D

Guest: Yang Xinyi, Head of AIDD at Henlius

Outline: 1. Antibody Toolchain 2. Large-scale Database

12:20-12:40 | Report: AI Drug Discovery - FAIR & FAIR

Guest: Han Liyan, Head of AIDD at Hengrui Medicine & Deputy General Manager of R&D at Hengrui Shanghai Shengdi

Outline: 1. Data FAIR and Agent FAIR 2. Interpreting the Data FAIR Principles 3. Proposing Standards for Agent FAIR

12:40-13:00 | Report: Iteration of AI Drug Discovery Engine MAP, Oral GLP-1 Small Molecule Design and Progress

Guest: Zhangming Niu, Founder & CEO of De Rui Zhi Yao

13:00-13:20 | Report: AI for Discovery: 3+1 Architecture and Closed-Loop Innovation

Guest: Fei Tang, Vice President of Pharmaceuticals at Hutchison Whampoa Limited

Outline: 1. AI 3+1 Research Intelligence Architecture: From Model Capabilities to System-Level Scientific Intelligence 2.Data Ontology Construction Logic: Driving Cross-Domain Data Unification and AI Cognitive Foundations 3 Case Study Sharing

13:20-13:40 | Report: Empowering Every Pharma Company with Its Own "AI Chief Scientist"

Guest: Xie Jie, COO of Shuimu Molecule

Outline: 1. Real Challenges in Implementing AI at Biopharma Companies 2. The Paradigm Shift from Conversational AI to Task-Oriented AI 3. Redefining Drug Discovery with Pharmaceutical Agents

13:40-14:40 | Interview: How AI and Pharmaceutical Companies Collaborate – From Technology Adoption to Capability Internalization

Moderator: Xiong Jian, Partner at Niukou Capital

Speakers: Wang Zheng, Head of R&D Computing and Intelligence, Shanghai Qilu Pharmaceutical Innovation Research Center; Zhou Jielong, Founder and CEO, Wanshi Wisdom; Xing Jie, COO, Shuimu Molecular; Zhang Wei, Professor, School of Business and Management, The University of Hong Kong; Zhu Feng, General Manager and Chief Digital & AI Officer, Henlius Biotech

14:00-16:00 | Brain-Computer Interface

14:00-15:00 | Report: Brain-Computer Interface Industry: Technology and Policy Synergy, Preparing for Rapid Growth

Guest: Dong Nan, Industrial Securities, Economic and Financial Research Institute, Pharmaceutical Analyst

Outline: 1. Overview and Policy Analysis of the Brain-Computer Interface Industry 2. Analysis of Underlying Signal Chains in BCI Systems 3. Detailed Examination of Invasive, Semi-Invasive, and Non-Invasive BCI Technologies and Clinical Applications

15:00-15:20 | Report: Digital Human Brain Modeling Empowers CNS Innovative Drug Development

Guest: Yan Yuxiang, CEO of Lingxi Cloud

Outline: 1. Foundation large models for brain-computer interfaces and individual digital human brain modeling technologies. 2. Patient selection, real-time efficacy response monitoring, and clinical trial outcome evaluation during drug clinical trials based on digital human brain modeling technology. 3. Drug target discovery, candidate indication analysis, and preclinical drug efficacy quantitative prediction based on digital human brain modeling technology.

15:20-15:40 | Report: Pending

Guest: Liu Bing, Founder & CEO of Mingshi Brain-Computer Interface

Special Guest

Dai Han

Chief Innovation Officer & Head of Investment & Strategy

VYBIO

Dongnan

Senior Researcher

Industrial Securities

Han Liyan

Head of AIDD Drug Discovery

Hengrui Medicine

Lai Caida

Co-Founder & CEO

Jitai Technology

Lin Dongqiang

Professor, School of Chemical Engineering and Biotechnology

Zhejiang University

Ma Junyi

Head of AI Strategy Development

Fosun Pharma

Ma Jun

PhD

Former Deputy General Manager of Junshi Biosciences

Ni Hua

Maiwei Biopharma

Shen Yuelei

Chairman and CEO

Biosynthe

Tang Defang

Vice General Manager

Chengdu Jingze Biology

Tang Fei

Vice President of Pharmaceutical Company

Hutchison MediPharma